INTRODUCTION

Oral squamous cell carcinomas (OSCC) constitute the sixth most common cancer diagnosed worldwide.\(^1\) In India, it is the leading cancer among men and the third most common among women. An estimate of 75,000-80,000 new cases are reported annually.\(^2,3\) Although, TNM staging is widely used to determine treatment options, it is not sufficient for optimal prognostication.

A distinctive feature of OSCC is that amongst patients with same stage and site of the tumor, some patients do better than others.\(^4\) This is because OSCC usually exhibit a heterogenous cell population with probable differences in the degree of differentiation; invasive and metastatic behaviour.\(^5-7\) Recent studies have demonstrated that cells at the invasive tumor front, bare morphological resemblance to the cells at central portion of the tumor, their molecular character differs significantly. E-cadherin is a cell-cell adhesion molecule that connects epithelial cells. This study attempts to correlate the E-cadherin expression at the invasive tumor front with tumor differentiation along with its clinico-pathological parameters.

Materials and Methods: Immunohistochemical staining with E-cadherin was carried out on archival cases of primary oral squamous cell carcinomas \((n = 30)\). The E-cadherin expression at the invasive tumor front was analyzed and was linked to clinico-pathological parameters including patient prognosis.

Results: The downregulation of E-cadherin expression at the invasive tumor edge when compared with patient’s prognosis yielded a significant correlation \((P = 0.041)\) but its correlation with the degree of differentiation determined was not significant \((P = 0.27)\). Also, its association with tumor size and lymph node status was negative.

Conclusions: Loss of E-cadherin expression at the invasive tumor front is an important event in the progression of oral squamous cell carcinomas. Tumors with a loss of expression of E-cadherin are those which had a poor prognosis.

Key words: Differentiation, E-cadherin, invasive tumor front, oral cancer, prognosis
such as aggressiveness of the tumor, enhanced invasive and metastatic potential of the tumor\textsuperscript{[15,14]} However, the reports on clinical significance of overall E-cadherin expression in whole tumor sections of OSCC are controversial. Decreased expression of E-cadherin was found to correlate significantly with poor prognosis by some researchers, while others could not obtain such results from their work\textsuperscript{[15-20]} In addition, the prognostic significance of the altered expression of E-cadherin at the invasive tumor front (ITF) in these tumors has not been widely explored\textsuperscript{[21]}

There has been an inference that the clinico-pathological and molecular profile of Indian carcinomas shows significant differences from oral cancers in several developed countries\textsuperscript{[22]} Earlier, the expression of E-cadherin at the superficial/central areas of the tumor had been assessed in OSCC from India\textsuperscript{[23]}. Thus, the objectives of this study were two-fold; (i) to examine the expression of E-cadherin at the ITF of the neoplasm, (ii) to correlate the expression of E-cadherin with tumor grade and with patient prognosis.

**MATERIALS AND METHODS**

**Tissue samples**

Formalin-fixed and paraffin-embedded tissue blocks of 30 cases of primary OSCC, 10 each of well, moderate and poorly-differentiated OSCC that underwent surgery as the only mode of treatment and with a follow-up record of 5 years in the period of 1995-2001 were drawn from the archives of the department. The clinical data regarding age, gender, site and TNM staging were also noted from the patient’s files. The 5-year follow-up data after surgery was also recorded and those cases that did not present with recurrence/death due to OSCC over this period were considered as the good prognosis group (11 cases) and those that did were categorized as poor prognosis group (19 cases). Five tissue specimens from the normal oral mucosa were included in the study to serve as positive controls.

**Immunohistochemistry**

Three fresh sections of 4-μm-thickness were cut from formalin-fixed and paraffin-embedded tissue blocks. The sections were taken onto 3-aminopropyltriethoxysilane (APES)-coated (slide adhesive) micro-slides. The sections were deparaffinized, washed in tris-buffer and treated with 0.3% hydrogen peroxide solution for 20 min in a humid chamber to block endogenous peroxidase. Antigen retrieval was done in tri-sodium citrate buffer (pH: 6.0-6.2) in a pressure cooker (2 whistles followed by cooling to room temperature). After blocking with protein block serum-free for 20 min, the sections were treated with pre-diluted, unlabeled primary antibody i.e. mouse-anti human E-cadherin (Clone No. 36, Biogenex Life Sciences Private Limited, CA, USA) at 37°C temperature, for 60 min in a humid chamber. The sections were then incubated with secondary-linking antibody (biotinylated anti-immunoglobulins/super enhancer) at room temperature, in a humid chamber for 30 min to enhance the effect of subsequent polymer step. The sections were incubated with pre-diluted secondary antibody, i.e. conjugate (enzyme-conjugated streptavidin) at room temperature for 30 min. This was followed by incubation with diaminobenzidine tetra hydrochloride and counterstained with Mayer’s hematoxylin. For negative control tissue, sections were treated with all the reagents except the primary antibody. The normal salivary glands tissue served as the internal positive control. The expression of E-cadherin protein was evaluated by two independent observers using a light microscope.

**Immunohistochemical analysis**

Semi-quantitative analysis was carried out by two authors under a light microscope (x400 original magnifications). The expression of E-cadherin in all the cases of primary OSCC was assessed at the ITF. Membranous expression of E-cadherin were graded into four subgroups according to Bankfalvi et al\textsuperscript{[15]} and is given in Table 1.

As for statistical analysis, A, B, C and D were defined as negative, weak, moderate and strong E-cadherin expression. Frequency and percentage were used to summarize distribution of prognosis across histopathology grade, tumor differentiation and E-cadherin expression. Chi-square test was used to test whether the distribution of prognosis across histopathology grade and E-cadherin expression was statistically significant. Analysis was carried out using Statistical Package for the Social Sciences software (SPSS 15.0) A P value of less than 0.05 was considered to be statistically significant.

**RESULTS AND OBSERVATIONS**

The study group comprised of 24 men and 6 women with an age range of 28-85 years (mean 60.3 years). As per the TNM staging (1987 UICC/AJCC classification), the cases of early stage (T1 and T2) were 10 and the advanced stages (T3 and T4) were 20 cases. Lymph node metastasis was present in 21 cases. Distant metastasis was not evident in any of the patients at the time of diagnosis.

Among the 10 cases of early stage tumors (T1 and T2), 6/10 (60%) of cases showed a moderate expression for E-cadherin. While, among the 20 cases of advanced stage...
tumors (T3 and T4), equal number of cases 9/20 (45%) showed moderate and strong E-cadherin expression. Among the nine cases that did not present with lymph node metastasis, five (55%) cases showed a moderate expression for E-cadherin. Among the 21 cases that were positive for lymph node metastasis, 10 cases (47%) showed a moderate expression for E-cadherin. No significant data was revealed from the staging system [Table 2].

All the tissue section of the normal oral epithelium showed complete cellular membranous staining of E-cadherin in the basal, parabasal and lower parts of the spinous layers [Figure 1]. Among the well-differentiated squamous cell carcinomas, 6 cases (60%) showed a moderate and 4 cases (40%) showed strong membranous expression of E-cadherin [Figure 2]. Among the moderately differentiated squamous cell carcinomas, 1 case (10%) showed a week expression, 4 cases (40%) moderate [Figure 3] and 5 cases (50%) showed strong membranous expression of E-cadherin. Among the poorly differentiated squamous cell carcinomas, 3 cases (30%) showed a week expression [Figure 4], 5 cases (50%) showed moderate and 2 cases (20%) showed strong membranous expression of E-cadherin. There was no significant ($P = 0.27$) loss of expression associated with the degree of differentiation [Table 3].

When the expression of E-cadherin was correlated with patient outcomes, 7/11 cases (63.6%) that had a good prognosis showed a strong positive expression of E-cadherin, while 11/19 (57.8%) cases of poor prognosis showed a moderate positive expression of E-cadherin [Table 4]. There was a significant ($P = 0.041$) reduction in the expression of E-cadherin among the cases with poor prognosis when compared with those of a good prognosis.
A summary of the E-cadherin expression between the different prognostic groups and within the different grades of the tumor is given in Table 5.

**DISCUSSION**

Cell-cell adhesion molecules play an important role in regulating the growth and differentiation of normal stratified squamous epithelia. E-cadherin is a primary mediator of these cell-cell adhesions between epithelial cells. It plays a crucial role in normal tissue morphogenesis, including segregation of cell types and differentiation.\[21,24\]

In the normal epithelium, E-cadherin is usually present in cells that have divided and moved into the differentiated layers. We found membranous expression of E-cadherin in the basal/parabasal and lower parts of the spinous layers of the normal oral mucosal tissues that served as control tissues for this study. In the superficial layers of the epithelium the expression of E-cadherin was reduced. Although, the mechanisms of regulation of E-cadherin expression in the upper layers of the epithelium are not understood, it is thought that the loss of expression may play a role in normal desquamation of the epithelium.\[15,24-28\]

In the present study, we found that most of the well-differentiated cases expressed a moderate or strong membranous expression for E-cadherin. Among the poorly differentiated cases, there were few cases that showed a negative or weak expression of E-cadherin. Thus, similar to Bankfalvi et al’s\[15\] study, no statistically significant result was recorded in our study. William et al.,\[27\] in their study found that 15/19 carcinoma cases showed loss of membranous staining for E-cadherin. All the four poorly differentiated cases in their study showed a loss of E-cadherin expression. This could be due to the limited number of cases that were analyzed and/or the differing profile at the ITF of Indian population.

Previous in vivo experiments have shown that the absence or loss of function of E-cadherin leads to the disappearance of epithelial characteristics of the cells and generates higher invasiveness for extracellular matrices and embryonal heart tissue.\[28,29\]

In this study, the size of tumor as per the WHO staging did not have a significant influence on the expression of E-cadherin. Wang et al., found a significant difference in the expression between T1/T2 tumors and T3/T4 tumors.\[21\] Bagutti et al., have shown that the least differentiated tumors showed a reduced expression of E-cadherin in the later stages and these tumor cells are said to acquire invasive phenotype.\[19\]

Detachment of tumor cells from the primary site is assumed to be the initial and most important step in the invasive and metastatic process.\[30,31\] E-cadherin negative tumors migrate from the primary site and colonize in the neighboring lymph nodes. Alternatively, lymphatic vessels might have better access to E-cadherin negative cells and these cells may be preferentially mobilized.\[14\]

Hubner et al., found that downregulation of E-cadherin expression in cancer cell is associated with occult metastasis in oral cavity and oropharyngeal squamous cell carcinomas. These findings support the function of E-cadherin in tumor suppression and lymphogenous metastasis in vivo.\[12\]
Along with downregulation of E-cadherin, Bryan et al. has summarized a phenomenon called “cadherin-switching” namely the upregulation of other members of the cadherin family like N-cadherin or P-cadherin has been found, which is also associated with worse outcome in case of bladder carcinoma.[32]

Similarly, increased N-cadherin expression was significantly correlated with malignant behaviours and cadherin switching was well correlated with histological differentiation, pattern of invasion and lymph node metastasis in head and neck OSCC cases.[33]

In the current study, we found 5/9 (55%) cases did not present with lymph node metastasis and showed a strong E-cadherin expression at the ITF. While 10/21 (47%) cases of tumors that presented with lymph node metastasis showed only a moderate expression of E-cadherin. Schipper et al. and Shiozaki et al., have reported that reduced staining for E-cadherin correlates with an invasive and metastatic behavior of OSCC.[14,34]

In vivo studies have shown that carcinoma cell lines with an epitheloid phenotype were non-invasive and expressed E-cadherin, while those with a fibroblastoid phenotype were invasive and had lost E-cadherin expression.[14] Thus, this significant loss of E-cadherin in metastasis reflects the “invasion suppressor function of this molecule”. [14,35]

The underlying molecular mechanism for E-cadherin downregulation in OSCC is not known. The CDH1 gene that is located on chromosome 16q22.1 encodes the epithelial specific cadherin glycoprotein. Mutations in this structural gene or due to indirect suppression of E-cadherin gene can result in the reduced expression of E-cadherin in malignancy.[36]

An intact E-cadherin/β-catenin complex is required for the maintenance of normal intercellular adhesion. Disturbances in the expression or function of these complexes result in loss of intercellular adhesion. The reduction/loss of cell-cell junctions as in E-cadherin could be either due to the mutations/abnormalities seen in the E-cadherin and/or its associated molecular complex involving catenins and actins, leading to disturbances in the normal architecture of the epithelium. Inversely, disturbed architecture, which occurs due to some other causes/mutations, can lead to disruption in the cadherin/catenin complex.[13,37]

When the prognostic significance of E-cadherin expression was examined, we found that all the cases 4/4 (100%) which showed a negative or mild E-cadherin were those that had a poor prognosis. Whereas, 7/11 (63.3%) cases that showed a strong E-cadherin expression were those that had a good prognosis and 11/15 (73.3%) cases that showed a moderate E-cadherin expression were those with a poor prognosis. Wang et al.,[21] also reported E-cadherin downregulation at the ITF in the poor prognosis group when compared with the good prognosis group. Sorscher et al.,[38] also suggested that the loss of expression was a marker for metastatic disease and was associated with a poorer prognosis of the tumor.

As the adhesive function of E-cadherin crucially depends on their association with cytoplasmic catenins, additional studies focusing on the ITF on a larger sample and along with these related cell adhesion molecules is necessary to evaluate the biological value of loss of E-cadherin in the progression of this neoplasm. These studies should focus on assessing the cadherin-catenin complex as well as cadherin switch at the ITF and attempt to understand the mechanisms by which disruption of these complexes occur.

CONCLUSION

This study shows that the loss of E-cadherin appears to be associated with poor prognosis of OSCCs. However, we could not find a correlation between clinico-pathological features and the loss of expression of E-cadherin. This could be attributed to limited sample size of the study or the different molecular profile of the tumor cells at the ITF of OSCC, in the Indian population. Studies need to be carried out on larger number of tumor specimens and the expression of E-cadherin should be assessed along with other molecules that play an important role in cell-cell contact between the epithelial cells.

REFERENCES

1. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocon 2000. Int J Cancer 2001;94:153-6.
2. Sankaranarayanan R. Oral cancer in India: An epidemiologic and clinical review. Oral Surg Oral Med Oral Pathol 1990;69:325-30.
3. National Cancer Registry Programme, Consolidated report of the population based cancer registries, 1990-1996. Indian Council of Medical Research, New Delhi, August 2001. Available from: www.icmr.nic.in/ncrp/ncrp_p/cancer_reg.pdf [Last accessed 2003 Jan 23].
4. Carlos de Vicente J, Junquera Gutiérrez LM, Zapatero AH, Fresno Forcelledo MF, Hernández-Velarde G, López Arranz JS. Prognostic significance of p53 expression in oral squamous cell carcinoma without neck metastases. Head Neck 2004;26:22-30.
5. Deisboeck TS, Couzin ID. Collective behavior in cancer cell populations. Bioessays 2009;31:190-7.
6. Monroe MM, Anderson EC, Clayburgh DR, Wong MH. Cancer stem cells in head and neck squamous cell carcinoma. J Oncol 2011;2011:762780.
7. Olsson L. Phenotype diversity of malignant cell populations: Molecular mechanisms and biological significance. Cancer Res 1986;3:91-114.
8. Byrne M, Koppang HS, Lillegard R, Kjaerheim A. Malignancy grading of the deep invasive margins of oral squamous cell carcinoma has high prognostic value. J Pathol 1992;166:375-81.
9. Byrne M, Boysen M, Alfsen CG, Abeler VM, Sudbo J, Nesland JM, et al. The invasive front of carcinomas. The most important area for tumor prognosis. Anticancer Res 1998;18:4757-64.
10. Bryne M, Koppang HS, Lillegård R, Stene T, Bang G, Dabelsteen E. New malignancy grading is a better prognostic indicator than Broders’ grading in oral squamous cell carcinoma. J Oral Pathol Med 1989;18:432-7.

11. Takeichi M. Cadherin cell adhesion receptors such as morphogenetic regulators. Science 1991;251:1451-5.

12. Huber GF, Züllig G, Soltermann A, Roessle M, Graf N, Haerle SK, et al. Down regulation of E-Cadherin (ECAD) – a predictor for occult metastatic disease in sentinel node biopsy of early squamous cell carcinomas of the oral cavity and oropharynx. BMC Cancer 2011;11:1-8.

13. Thomas GJ, Speight PM. Cell adhesion molecules and oral cancer. Crit Rev Oral Biol Med 2001;12:479-98.

14. Schipper JH, Fri xen Uh, Behrens J, Unger A, Jahnke K, Birchmeier W. E-cadherin expression in squamous cell carcinomas of head and neck: Inverse correlation with tumor dedifferentiation and lymph node metastasis. Cancer Res 1991;51:6328-37.

15. Bánkfalvi A, Krassort M, Végh A, Felszeghy E, Piffkó J. Deranged expression of the E-cadherin/beta-catenin complex and the epidermal growth factor receptor in the clinical evolution and progression of oral squamous cell carcinomas. J Oral Pathol Med 2002;31:450-7.

16. Mattijssen V, Peters HM, Schalkwijk L, Manni JJ, van’t Hof-Grootenboer B, de Mulder PH, et al. E-cadherin expression in head and neck squamous-cell carcinoma is associated with clinical outcome. Int J Cancer 1993;55:580-5.

17. Shinohara M, Hiraki A, Ikebe T, Nakamura S, Kurahara S, Shirasuna K, et al. Immunohistochemical study of desmosomes in oral squamous cell carcinoma: Correlation with cytokeratin and E-cadherin staining, and with tumour behavior. J Pathol 1998;184:369-81.

18. Hoteiya T, Hayashi E, Satomura K, Kamata N, Nagayama M. Expression of E-cadherin in oral cancer cell lines and its relationship to invasiveness in SCID mice in vivo. J Oral Pathol Med 1999;28:107-11.

19. Bagutti C, Speight PM, Watt FM. Comparison of integrin, cadherin, and catenin expression in squamous cell carcinomas of the oral cavity. J Pathol 1998;186:8-16.

20. Muñoz-Guerra MF, Marazuela EG, Fernández-Contreras ME, Gamallo C. P-cadherin expression reduced in squamous cell carcinoma of the oral cavity: An indicator of poor prognosis. Cancer 2005;103:960-9.

21. Wang X, Zhang J, Fan M, Zhou Q, Deng H, Aisharif MJ, et al. The expression of E-cadherin at the invasive tumor front of oral squamous cell carcinoma: Immunohistochemical and RT-PCR analysis with clinicopathological correlation. Oral Surg Oral Med Oral Radiol Endod 2009;107:547-54.

22. Teni T, Pawar S, Sanghvi V, Saranath D. Expression of bcl-2 and bax in chewing tobacco-induced oral cancers and oral lesions from India. Pathol Oncol Res 2002;8:109-14.

23. Kaur G, Carmelio S, Rao N, Rao L. Expression of E-cadherin in primary oral squamous cell carcinoma and metastatic lymph nodes: An immunohistochemical study. Indian J Dent Res 2009;20:71-6.

24. Mahomed F, Altini M, Meer S. Altered E-cadherin/b-catenin expression in oral squamous carcinoma with and without nodal metastasis. Oral Dis 2007;13:386-92.

25. Jankowski J, Newham P, Kandemir O, Hirano S, Takeichi M, Pignatelli M. Differential expression of e-cadherin in normal, metaplastic and dysplastic esophageal mucosa- a putative biomarker. Int J Oncol 1994;4:441-8.

26. Vessey CJ, Wilding J, Folarin N, Hirano S, Takeichi M, Soutter P, et al. Altered expression and function of E-cadherin in cervical intraepithelial neoplasia and invasive squamous cell carcinoma. J Pathol 1995;176:151-9.

27. Williams HK, Sanders DS, Jankowski JA, Landini G, Brown AM. Expression of cadherins and catenins in oral epithelial dysplasia and squamous cell carcinoma. J Oral Pathol Med 1998;27:308-17.

28. Fri xen UM, Behrens J, Sachs M, Eberle G, Voss B, Warda A, et al. E-cadherin-mediated cell-cell adhesion prevents invasiveness of human carcinoma cells. J Cell Biol 1991;113:173-85.

29. Behrens J, Mareel MM, Van Roy FM, Birchmeier W. Dissecting tumor cell invasion: Epithelial cells acquire invasive properties after the loss of uromorulin-mediated cell-cell adhesion. J Cell Biol 1989;108:2435-47.

30. van Zijl F, Krupitzka G, Mikulitis W. Initial steps of metastasis: Cell invasion and endothelial transmigration. Mutat Res 2011;728:23-34.

31. Sahai E. Illuminating the metastatic process. Nat Rev Cancer 2007;7:737-49.

32. Bryan RT, Tselepis C. Cadherin switching and bladder cancer. J Urol 2010;184:423-31.

33. Nguyen PT, Kudo Y, Yoshid M, Kamata N, Ogawa I, Takata T. N-cadherin expression is involved in malignant behaviour of head and neck cancer in relation to epithelial-mesenchymal transition. Histol Histopathol 2011;26:147-56.

34. Shiozaki H, Tahara H, Oka H, Miyata M, Kobayashi K, Tamura S, et al. Expression of immunoreactive E-cadherin adhesion molecules in human cancers. Am J Pathol 1991;139:17-23.

35. Bánkfalvi A, Krassort M, Buchwalow IB, Végh A, Felszeghy E, Piffkó J. Gains and losses of adhesion molecules (CD44, E-cadherin, and beta catenin) during oral carcinogenesis and tumour progression. J Pathol 2002;198:16.

36. Sorscher SM, Russack V, Cagle M, Feramisco JR, Green MR. Immunohistochemical localization of E-cadherin in head and neck cancer. Arch Pathol Lab Med 1995;119:82-4.

How to cite this article: Mehendiratta M, Solomon MC, Boaz K, Guddattu V, Mohindra A. Clinico-pathological correlation of E-cadherin expression at the invasive tumor front of Indian oral squamous cell carcinomas: An immunohistochemical study. J Oral Maxillofac Pathol 2014;18:217-22.

Source of Support: Nil. Conflict of Interest: None declared.